Free Ropinirole Adhesive Patch Stability

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Transdermal absorption preparations using acid addition salts of ropinirole have lower permeability and stability issues due to incomplete conversion and potential metal salt precipitation, leading to skin irritation and physical deterioration of patches.

Innovation Solution

A transdermal absorption patch with an acrylic-based adhesive containing no cross-linking agent, hydroxyl or pyrrolidone groups, and free ropinirole, optionally enhanced with transdermal absorption enhancers, antioxidants, and other additives, ensuring complete dissolution and stability of the drug.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If acid addition salt of ropinirole is used in transdermal absorption preparation, then stability and handleability are improved, but transdermal absorbability is significantly reduced

Engineering Contradiction:
Improvedrug stabilityVSAvoidtransdermal absorbability
Core Design Contradiction:
ReliabilityVSProductivity

Solution Approach 1:

The invention changes the chemical form parameter of ropinirole from acid addition salt to free base form, enabling high transdermal absorbability while maintaining stability through specific adhesive base composition (acrylic polymer with hydroxyl or carboxyl groups)

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The acrylic-based adhesive base acts as an intermediary medium that facilitates the conversion and stabilization of ropinirole free base, enabling it to maintain stability during storage while achieving high transdermal absorption

Inventive Principle:
Principle #24Intermediary (Mediator)

2Productivity

If dehydrochlorinating agent is used to convert acid addition salt to free ropinirole, then transdermal absorbability is improved, but the amount of drug in adhesive base is limited and conversion is incomplete

Engineering Contradiction:
Improvetransdermal absorbabilityVSAvoidconversion completeness
Core Design Contradiction:
ProductivityVSManufacturing precision

Solution Approach 1:

The invention performs preliminary action by directly using free ropinirole base form in the formulation, avoiding the need for dehydrochlorinating agents and ensuring complete drug availability from the start

Inventive Principle:
Principle #10Preliminary action

3Productivity

If dehydrochlorinating agent is used for conversion, then free ropinirole is generated, but metal salt precipitates causing physical deterioration and skin irritation

Engineering Contradiction:
Improvefree drug availabilityVSAvoidmetal salt precipitation
Core Design Contradiction:
ProductivityVSObject-generated harmful factors

Solution Approach 1:

The invention extracts and eliminates the need for dehydrochlorinating agents and metal salts by directly formulating with free ropinirole base, removing the source of metal salt precipitation and associated harmful effects

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The invention converts the potential harm of metal salt precipitation into benefit by using an acrylic-based adhesive base that chelates or complexes with any residual metal ions, preventing precipitation while maintaining drug stability

Inventive Principle:
Principle #22Blessing in disguise (Convert harm into benefit)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The patch achieves high transdermal absorbability and stability of free ropinirole, effectively treating Parkinson's disease with improved drug release and skin compatibility.

Implementation Method 1

the adhesive base consists of (1) an acrylic-based adhesive containing no cross-linking agent, having no carboxyl group and having a hydroxyl group or a pyrrolidone group, (2) free ropinirole

Methodology Applied
Scientific EffectSolvation: Solvation

Implementation Method 2

one or more component(s) selected from the group consisting of a transdermal absorption enhancer

Methodology Applied
Scientific EffectPermeation: Permeation

Data Source

PatentEP2786752B1Ropinirole-containing adhesive patch
Publication Date: 2019.06.12 TEIKOKU SEIYAKU CO LTD
  • EP2786752B1 patent drawingFigure 1~2
  • EP2786752B1 patent drawingFigure 3~4
  • EP2786752B1 patent drawingFigure 5~6

AI summary

Provided is an adhesive patch containing ropinirole serving as a therapeutic drug for Parkinson's disease, with the ropinirole used being free ropinirole (ropinirole in free form) added to an adhesive base, wherein the patch exhibits favorable drug permeability and excellent drug stability. Also provided is a transdermal absorption patch using, as an adhesive base, an acrylic-based adhesive having no specific carboxyl group and having a hydroxyl group or a pyrrolidone group, with the patch including free ropinirole added to the adhesive base. Further provided is a ropinirole-containing transdermal absorption patch including a transdermal absorption promoting agent.